<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Merck.com - Research &amp; Development News</title>
<link>http://www.merck.com/newsroom/press_releases/research_and_development/</link>
<description>Merck.com - Research &amp; Development News</description>
<image>
	<title>Merck.com - Research &amp; Development News</title>
	<width>142</width>
	<height>42</height>
	<link>http://www.merck.com/newsroom/press_releases/research_and_development/</link>
	<url>http://www.merck.com/site_images/mercklogo-rss.jpg</url>
</image>
<item>
	<title>Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)</title>
	<guid isPermaLink="false">MerckReceivesNot04/28/2008</guid>
	<link>http://www.merck.com/newsroom/press_releases/research_and_development/2008_0428.html?src=rss</link>
	<pubDate>Mon, 28 Apr 2008 00:00:00 GMT</pubDate>
</item>
<item>
	<title>Schering-Plough/Merck Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast</title>
	<guid isPermaLink="false">ScheringPloughMe04/25/2008</guid>
	<link>http://www.merck.com/newsroom/press_releases/research_and_development/2008_0425.html?src=rss</link>
	<pubDate>Fri, 25 Apr 2008 00:00:00 GMT</pubDate>
</item>
<item>
	<title>Two Merck Medicines Recommended for Approval in the European Union</title>
	<guid isPermaLink="false">TwoMerckMedicine04/24/2008</guid>
	<link>http://www.merck.com/newsroom/press_releases/research_and_development/2008_0424.html?src=rss</link>
	<pubDate>Thu, 24 Apr 2008 00:00:00 GMT</pubDate>
</item>
</channel>
</rss>